Beigene Ltd
SSE:688235

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
SSE:688235
Watchlist
Price: 164 CNY 0.99% Market Closed
Market Cap: 146.3B CNY
Have any thoughts about
Beigene Ltd?
Write Note

Operating Margin
Beigene Ltd

-27.4%
Current
-104%
Average
-7.9%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.4%
=
Operating Profit
-6.5B
/
Revenue
23.7B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KY
Beigene Ltd
SSE:688235
146.3B CNY
-27%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.6B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.2B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
117.2B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
136.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-22%
Country KY
Market Cap 146.3B CNY
Operating Margin
-27%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.6B USD
Operating Margin
28%
Country US
Market Cap 141.2B USD
Operating Margin
19%
Country US
Market Cap 117.2B USD
Operating Margin
38%
Country US
Market Cap 105.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 136.4B AUD
Operating Margin
26%
Country US
Market Cap 78.4B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36.2B EUR
Operating Margin
-22%
No Stocks Found

Beigene Ltd
Glance View

Market Cap
146.3B CNY
Industry
Biotechnology

BeiGene Ltd., a global powerhouse in biopharmaceutical innovation, traces its journey back to its roots in Beijing, having established itself with a clear vision—to address the vast unmet needs in cancer treatment. Co-founded by John V. Oyler in 2010, the company set out on a mission to develop effective and accessible therapies for cancer patients worldwide. Operating at the intersection of cutting-edge science and global entrepreneurship, BeiGene built its reputation by investing heavily in research and development. The crux of its model hinges on leveraging both in-house capabilities and strategic collaborations. This has allowed it to expedite the development of a rich pipeline of oncology therapies, with a focus on small molecule drugs and monoclonal antibodies, navigating the complex world of biotechnology to bring pioneering solutions to market. Central to BeiGene's financial engine is its adeptness at creating a portfolio of marketable cancer therapies, primarily through licensing agreements and strategic partnerships. The company's business model thrives on advancements like Brukinsa, a treatment for certain types of lymphoma, which has seen significant regulatory approvals worldwide. Partnerships with pharmaceutical giants, such as Amgen, have amplified its global reach, enabling it to widen its distribution network beyond China to North America and Europe. By embedding itself into various markets and healthcare systems, BeiGene captures revenue through product sales, milestone payments, royalties, and collaboration fees. This multifaceted approach not only spearheads its growth trajectory but also solidifies its reputation as a company committed to combating cancer on a global scale, driven by innovation and an unwavering dedication to its mission.

Intrinsic Value
844.93 CNY
Undervaluation 81%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-27.4%
=
Operating Profit
-6.5B
/
Revenue
23.7B
What is the Operating Margin of Beigene Ltd?

Based on Beigene Ltd's most recent financial statements, the company has Operating Margin of -27.4%.